5-morpholinopyridine-3,4-diamine | 1314734-64-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-morpholinopyridine-3,4-diamine
• 英文别名: 5-morpholin-4-ylpyridine-3,4-diamine
• CAS: 1314734-64-9
• 化学式: C₉H₁₄N₄O
• 分子量: 194.236
• InChiKey: QHZAQWKHDCSPCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  77.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-morpholinopyridine-3,4-diamine 、 5-(4-氟苯)-[1,3,4]恶二唑-2-胺 生成 5-(4-fluorophenyl)-N-(7-morpholino-1H-imidazo[4,5-c]pyridin-2-yl)-1,3,4-oxadiazol-2-amine
  参考文献：
  名称：

  Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis

  摘要：

  Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-2α and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-2α or iron metabolism.

  公开号：

  US20220281862A1
• 作为产物：
  描述：

  4-氨基-3-硝基吡啶 在 palladium 10% on activated carbon 氢气 、 溴 、 sodium acetate 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 28.0h， 生成 5-morpholinopyridine-3,4-diamine
  参考文献：
  名称：

  [EN] 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF
  [FR] 1H-PYRAZOLO[3,4-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  本文提供了按照式（I）的化合物及其药用盐，以及包含它们的组合物，用于各种方法，包括治疗结肠癌、卵巢癌、胰腺癌、乳腺癌、肝癌、前列腺癌和血液系统肿瘤。

  公开号：

  WO2011084486A1

文献信息

• [EN] SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] BENZIMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：BIAL BIOTECH INVEST INC

  公开号：WO2021055591A1

  公开（公告）日：2021-03-25

  The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

  这项发明提供了替代苯并咪唑羧酰胺及相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗疾病的方法，例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病。
• INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF
  申请人：SAMUMED, LLC

  公开号：US20130267495A1

  公开（公告）日：2013-10-10

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地，本发明涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征化的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎）、调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而引起的遗传疾病和神经系统疾病/疾患。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF<br/>[FR] INHIBITEURS D'INDAZOLE DU TRAJET DE SIGNAL DE WNT ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2013151708A1

  公开（公告）日：2013-10-10

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. One embodiment disclosed herein includes a compound having the structure of Formula I:

  本发明揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地，本发明涉及使用吲唑化合物或其类似物治疗由Wnt通路信号激活引起的障碍（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或一个或多个Wnt信号传递组分的突变或失调而引起的遗传疾病和神经状况/紊乱/疾病。还提供了治疗Wnt相关疾病状态的方法。本文所披露的一种实施例包括具有式I结构的化合物：
• 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF
  申请人：Hood John

  公开号：US20110190290A1

  公开（公告）日：2011-08-04

  Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:

  本文提供符合I式的化合物及其药学上可接受的盐，以及包含它们的组合物，用于各种方法，包括治疗结肠癌、卵巢癌、胰腺癌、乳腺癌、肝癌、前列腺癌和血液学癌症。
• 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
  申请人：Samumed, LLC

  公开号：US08901150B2

  公开（公告）日：2014-12-02

  Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:

  本文提供了符合公式I的化合物及其药学上可接受的盐，并且包括这些化合物的组合物，用于各种方法，包括治疗结肠癌、卵巢癌、胰腺癌、乳腺癌、肝癌、前列腺癌和血液系统肿瘤等癌症。